Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.60 |
| ▸ | ELANE | P08246 | 13/20 | 0.51 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 5/20 | 0.45 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8409559 | 0.87 | TRIM24 (0.60) | ERN1ELANEPRTN3CA2TRIM24 | |
| SCHEMBL7531725 | 0.83 | ELANE (0.50) | ELANEPRTN3CA2 | |
| SCHEMBL10774506 | 0.81 | ERN1 (0.66) | ERN1TRIM24TYRTRIM33 | |
| SCHEMBL19558305 | 0.78 | ELANE (0.56) | ELANECA2 | |
| SCHEMBL19718952 | 0.78 | ELANE (0.68) | ELANECA2 | |
| SCHEMBL6665857 | 0.77 | ERN1 (0.60) | ERN1ELANETRIM24TYRTRIM33 | |
| SCHEMBL4876550 | 0.77 | ERN1 (0.60) | ERN1ELANECA2TRIM24TYR | |
| SCHEMBL19335493 | 0.77 | ELANE (0.55) | ELANECA2 | |
| SCHEMBL18157016 | 0.77 | NR1H4 (0.60) | ELANETYR | |
| SCHEMBL21499751 | 0.76 | ERN1 (0.54) | ERN1CA2TRIM24TYRTRIM33 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350076-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090030056-A1 | NOVEL SODIUM CHANNEL BLOCKERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090030056-A1 | NOVEL SODIUM CHANNEL BLOCKERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2009-01-29 | — | — | US | disclosed |
| US-7439383-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439383-B2 | Sodium channel blockers | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-10-21 | — | — | US | disclosed |
| EP-0733033-B1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LTD (GB) | 1999-12-22 | — | — | EP | disclosed |
| EP-0778821-B1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LTD (GB) | 1999-10-20 | — | — | EP | disclosed |
| US-5965741-A | ANTIINFLAMMATORY, ANTIPYRETIC AND ANTIDIARRHOEAL PROPERTIES | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| US-5811459-A | PAIN RELIEVERS | ZENECA LIMITED (GB) | 1998-09-22 | — | — | US | disclosed |
| EP-0778821-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1997-06-18 | — | — | EP | disclosed |
| EP-0733033-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996011902-A1 | PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS | ZENECA LIMITED (GB) | 1996-04-25 | — | — | WO | disclosed |
| WO-1996006822-A1 | ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF | ZENECA LIMITED (GB) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030056-A1 | NOVEL SODIUM CHANNEL BLOCKERS | SCNN1B, SCN1B, KCNN2 | ERN1 4310/4885ELANE 4200/4885PRTN3 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.